bioAffinity shares surge 22.22% intraday after clinical case study boosts CyPath Lung adoption and 2025 revenue growth.

bioAffinity Technologies (BIAF) surged 22.22% intraday following the release of a clinical case study highlighting the effectiveness of its CyPath Lung test in diagnosing benign pulmonary nodules, reducing the need for invasive procedures. The study demonstrated 92% sensitivity and 88% accuracy for small nodules, while the company reported an 87% year-over-year revenue growth for CyPath Lung in 2025 and a 99% increase in test volumes. These developments, coupled with expanded adoption by physician offices and a strategic shift toward high-margin diagnostics, bolstered investor confidence during the session. Earlier premarket declines (3.09% and 11.31%) were attributed to broader market anxieties and sector-specific risks but were overshadowed by the immediate positive catalysts driving the intraday rally.